Zynerba Pharmaceuticals Inc logo

ZYNE

Zynerba Pharmaceuticals Inc

$1.25

Earnings Summary

Revenue
$0Mn
Net Profits
$-8.49Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

Zynerba Pharmaceuticals Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, Zynerba Pharmaceuticals Inc has generated NaN% jump in its revenue since last 3-months.

Net Profits:

Zynerba Pharmaceuticals Inc’s net profit fell -6.64% since last year same period to $-8.49Mn in the Q1 2022. On a quarterly growth basis, Zynerba Pharmaceuticals Inc has generated 3.68% jump in its net profits since last 3-months.

Net Profit Margins:

Zynerba Pharmaceuticals Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, Zynerba Pharmaceuticals Inc has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Zynerba Pharmaceuticals Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.23
EPS Estimate Current Year
-0.23

Highlights

EPS Estimate Current Quarter:

Zynerba Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.23 - a 0% jump from last quarter’s estimates.

EPS Estimate Current Year:

Zynerba Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.23.

Key Ratios

Key ratios of the Zynerba Pharmaceuticals Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.21
Return on Assets (ROA)
-0.3
Return on Equity (ROE)
-0.57
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Zynerba Pharmaceuticals Inc’s earning per share (EPS) fell -5% since last year same period to -0.21 in the Q1 2022. This indicates that the Zynerba Pharmaceuticals Inc has generated -5% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Zynerba Pharmaceuticals Inc’s return on assets (ROA) stands at -0.3.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Zynerba Pharmaceuticals Inc’s return on equity (ROE) stands at -0.57.

Dividend Per Share (DPS):

Zynerba Pharmaceuticals Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-16
-0.23
-0.21
8.7%

Company Information

Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. Zynerba Pharmaceuticals is committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies.

Organisation
Zynerba Pharmaceuticals Inc
Headquarters
Devon, Pennsylvania, US
Employees
26
Industry
Health Technology
CEO
Armando Anido